The BVA-100 (Blood Volume Analyzer) is a revolutionary instrument, developed by DAXOR Corporation and cleared by the FDA, to precisely measure blood volume in the human body.

Read More

Key Features

  • Superior  blood volume measurement
  • Results in under 1 hour
  • Clinically proven — used in leading hospitals

Latest News

Daxor Receives Two Patents, One for Measurement of Total Body Albumin and a Second Patent for Improved Accuracy of Blood Volume Measurement

Daxor has received approval from the US Patent Office for a Total Body Albumin Analyzer, US Patent # 9,002,656. The patent for the total body albumin analyzer is the first one issued for an instrument to measure the total albumin within the human body.  Albumin is the major carrier molecule in the human body for […]

Read More

Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as President and Chief Executive Officer on a Temporary Basis

Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as President and Chief Executive Officer on a Temporary Basis Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today along with the appointment of Michael Feldschuh, currently Executive Vice President, as […]

Read More

Daxor Announces Filing of Form N-Q for September 30, 2015

Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed an unaudited Form N-Q on Tuesday, November 24th disclosing its schedule of portfolio holdings as of September 30, 2015.Copies of the form are available on the Company’s website at http://www.daxor.com/pdfs/Daxor_NQ_11_24_15.pdf. Daxor has been reporting as an investment company under the Investment Company Act […]

Read More